Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial

Jian Lyu, Yan-Ming Xie, Zhan Gao, Jian-Wu Shen, Yue-Yi Deng, Song-Tao Xiang, Wen-Xi Gao, Wen-Tong Zeng, Chun-He Zhang, Dan-Hui Yi, Lian-Xin Wang, Zhi-Fei Wang, Jian Lyu, Yan-Ming Xie, Zhan Gao, Jian-Wu Shen, Yue-Yi Deng, Song-Tao Xiang, Wen-Xi Gao, Wen-Tong Zeng, Chun-He Zhang, Dan-Hui Yi, Lian-Xin Wang, Zhi-Fei Wang

Abstract

Background: Acute uncomplicated lower urinary tract infection (UTI) is one of the most common bacterial infections. Patients usually present with dysuria, urinary urgency, urinary frequency, and suprapubic pain or tenderness. Approximately 150 million people are diagnosed with UTI each year worldwide. The high recurrence rate of lower UTI is a common problem of clinical treatment. The misuse of antibiotics has led to the emergence of a number of resistant bacterial strains. Thus, traditional Chinese medicine is considered as an alternative option for treating acute uncomplicated lower UTI. Thus, this study aims to evaluate the efficacy and safety of Sanjin tablets (SJT) for the treatment of acute uncomplicated lower UTI, explore whether SJT can reduce or substitute the use of antibiotics, and reduce the recurrence rate in the treatment of acute uncomplicated lower UTI.

Methods/design: In this study, a randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical study will be established. A total of 252 patients with acute uncomplicated lower UTI (syndrome of dampness-heat in the lower jiao) will be randomly allocated in the ratio of 1:1:1 to three groups: experimental group; control group 1; and control group 2. The experimental group receives Sanjin tablets plus levofloxacin tablets (LT) placebo; the control group 1 receives LT plus SJT placebo; and the control group 2 receives SJT plus LT on the first five days, SJT plus LT placebo on the last two days. Each group will be treated for seven days and followed-up 1-2 times. The primary outcome measures of effective rate and recurrence rate are symptoms. Secondary outcome measures of effective rate and recurrence rate are the urine leukocytes, bacteriology examination, and safety assessment. Outcomes will be assessed at baseline and after treatment.

Discussion: This study protocol will provide the research data of efficacy and safety of SJT for the treatment of acute uncomplicated lower UTI. The first aim is to determine whether Sanjin tablets can reduce the use of antibiotics; the second aim is to determine whether Sanjin tablets can substitute the use of antibiotics. The recurrence rate will be assessed after cured to determine whether SJT can reduce the recurrence rate. The results of this study will improve the rational use of drugs, especially the rational application of antibiotics. It will also enable safety evaluation from laboratory indices and adverse events, which will provide reliable evidence for clinical treatment.

Trial registration: ClinicalTrials.gov, NCT03658291 . Registered on 4 September 2018.

Keywords: Acute uncomplicated UTI; Clinical trials; Randomized controlled trial; Sanjin tablets; Syndrome of dampness-heat in the lower jiao.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram. SJT Sanjin tablets, LT levofloxacin tablets
Fig. 2
Fig. 2
Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure

References

    1. Foxman B. Urinary tract infection syndromes occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin N Am. 2014;28(1):1–13. doi: 10.1016/j.idc.2013.09.003.
    1. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dm Disease-a-Month. 2003;49(2):53–70. doi: 10.1067/mda.2003.7.
    1. Khoshnood S, Heidary M, Mirnejad R, et al. Drug-resistant gram-negative uropathogens: A review. Biomed Pharmacother. 2017;94:982–994. doi: 10.1016/j.biopha.2017.08.006.
    1. El Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and patterns of differences in infectious disease mortality among US counties, 1980–2014. JAMA. 2018;319(12):1248–1260. doi: 10.1001/jama.2018.2089.
    1. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242–258. doi: 10.1080/00325481.2017.1246055.
    1. Peng YX, Liu XQ, Wen LL, et al. Antibacterial activities of five Chinese medicines of Rhei Radiset Rhizoma and their chemical constituents against multidrug-resistant clinical bacteria isolates. Chinese J Exp Tradit Med Formulae. 2014;20(22):103–107.
    1. Li DY, Hou Y, Zhang KY, et al. Research progress on mechanism of anti-drug resistance of traditional Chinese medicine. China Med Eng. 2017;25(11):16–19.
    1. Hou X, Wang LX. Research progress of Sanjin tablets. Eval Anal Drug Chin Hosp. 2016;16(08):1148–1151.
    1. Yi JC. Clinical observation of levofloxacin and Sanjin tablets in the treatment of urinary tract infection. JiangXi Med J. 2015;50(5):447–448.
    1. Dong XL. Clinical efficacy and safety of Sanjin tablets combined with levofloxacin tablet in the treatment of urinary tract infection. The World’s Latest Medical Information Abstracts. 2017;17(30):169–170.
    1. Zheng HY, Hu JG. Efficacy of Sanjin tablets combined with gatifloxacin in the treatment of acute simple lower urinary tract infection [J] Zhejiang J Integr Tradit Chin West Med. 2013;23(9):724–726.
    1. Meng J, Zou Z, Lu C, et al. Identification and characterization of bioactive compounds targeting uropathogenic Escherichia coli from Sanjin tablets. J Chem. 2015;2015:789809. doi: 10.1155/2015/789809.
    1. Pu X, Zhang LY, Zhang JH. A systematic review of Sanjin tablets in the treatment of simple urinary tract infection: a randomized controlled trial. Lishizhen Medicine and Materia Medica Research. 2016;27(4):1012–1014.
    1. Li WH, Zhu WT, Han L, et al. Pharmacoeconomic analysis of two integrated traditional and western treatment formulas of lower urinary tract infection. Chin Arch Tradit Chin Med. 2012;30(2):303–305.
    1. Hawkey PM. Multidrug-resistant Gram-negative bacteria: a product of globalization. J Hosp Infect. 2015;89(4):241–247. doi: 10.1016/j.jhin.2015.01.008.
    1. Penchovsky R, Traykovska M. Designing drugs that overcome antibacterial resistance: where do we stand and what should we do? Expert Opin Drug Discovery. 2015;10(6):631–650. doi: 10.1517/17460441.2015.1048219.
    1. World Medical Association World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
    1. National Medical Products Administration. Good Clinical Practice of Pharmaceutical Products. 2003-8-6. .
    1. Flory J, Emanuel E. Interventions to improve research participants’ understanding in informed consent for research - A systematic review. JAMA. 2004;292(13):1593–1601. doi: 10.1001/jama.292.13.1593.
    1. Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol. 2008;9(5):485–493. doi: 10.1016/s1470-2045(08)70128-1.
    1. DiNubile MJ. Double-blind active-control trials: Beware the comparator you keep. Clin Infect Dis. 2008;47(8):1064–1067. doi: 10.1086/592068.
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care-Assessing the quality of controlled clinical trials. Br Med J. 2001;323(7303):42–46. doi: 10.1136/bmj.323.7303.42.
    1. Chan AW, et al. SPIRIT 2013 statement: defining standard protocol items forclinical trials. Ann Intern Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Antes G. The new CONSORT statement. BMJ. 2010;340:c1432. doi: 10.1136/bmj.c1432.
    1. Liu H, Xie JX, Xu ZS. Clinical study of Sanjin pills to acute simple bacterial lower urinary tract infection based on the contrast of levofloxacin tablets. Acta Chinese Med. 2017;32(12):2489–2492. doi: 10.4103/0366-6999.216401.
    1. Na YQ, Sun G, Ye ZQ, et al. Guidelines for the diagnosis and treatment of Urological Diseases in China (2014 ed) Beijing: People’s Medical Publishing House; 2013.
    1. Wu HX. The National Standard Clinic Terminology of Traditional Chinese Medical Diagnosis and Treatment Was Released and Implemented. Chin J Inform Tradit Chin Med. 1998;05:25.
    1. Tian DL. Internal Medicine of Traditional Chinese Medicine. Beijing: Chinese Medicine Press; 2005.
    1. Jiang CB, Song YL, Ren Y, et al. Clinical Observation on the Effect of Jiawei Zishen Tongguan Decoction in Treating Stranguria of Kidney Deficiency and Dampness-Heat Syndrome. Chin J Integr Tradit West Nephrol. 2015;16(8):712–714.
    1. Yan SY, He LY, Liu BY. How to Keep the Blinding of Clinical Trials in Chinese Medicine. Modernization of Traditional Chinese Medicine and Materia Medical. 2014;16(12):2527–2530.
    1. Hu LP, Bao XL, Wang Q. Methods and analysis of realizing randomized grouping. J Chin Integr Med. 2011;9(7):711–714. doi: 10.3736/jcim20110703.
    1. Dalhoff A, Schubert S, Vente A. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections. Antimicrob Agents Chemother. 2017;61(5):e02446–e02416. doi: 10.1128/aac.02446-16.
    1. Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006;68:318–323. doi: 10.1016/j.urology.2006.02.042.
    1. Homma Y, Yoshida M, Obara K, et al. Development and validity of the Overactive Bladder Symptom Score (OABSS) urodynamics. Neurourol Urodyn. 2003;22:105–108. doi: 10.1002/nau.10099.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅